Lymphomatoid papulosis(LyP) is a chronic recurrent dermatosi characterized by involuting and recurring papules, plaques, and nodules showing histologic feaurs suggesting rnalignant lymphoma. On histologic ground, it is divided into two types. type A and type B. In type A, large atypical lymphocytes are the main cellular cornponent and most of these express CD 30(Ki-1) antigen, which has been p!reviously thought to be specific for Read Sternberg cells of Hodgkins disease. In type B, cerebriform mononuclear lymphocytes sirr la to those in mycosis fungoides predominates. We report two cases of lymphomatoid papulosis, type A and type B, respectively. The large atypical cells in type A LyP expressed Ki 1 antigen. Both case were treated with PUVA and the outcome of the treatment has been fair.
Antigens, CD30 ; Hodgkin Disease ; Lymphocytes ; Lymphoma ; Lymphomatoid Papulosis ; Mycosis Fungoides

An activation antigen, CD30 was initially identified on Hodgkin and Reed-Sternberg (H-RS) cells. CD30 expression is observed on activated, but not on resting, T and B lymphocytes. Despite of numerous studies, the functions of CD30 in physiological condition remains open question. Moreover, CD30 expression of normal B lymphocytes has been poorly documented. In this study, CD30 expression of murine B lymphocytes and its regulation was analyzed. Murine splenic B (SP-B) cells obtained by adherence were used for activation with LPS or plate-bound anti-mouse IgM. LPS stimulation resulted in B cell proliferation. However, stimulation with plate-bound anti- mouse IgM (pb anti-mlgM) induced blast cell formation but did not increase cell number. Both stimulation induced minimal expression of CD30. Substantial CD30 expression of SP-B cells was induced by IL 4, which upregulated both of proliferation and CD30 expression of activated SP-B cells. Highest level of CD30 expression was detected at day 3 of stimulation. IL 2 enhanced B cell proliferation but not CD30 expression and rather reduced IL 4-mediated upregulation of CD30 expression. These data suggest that the signaling pathway for B cell proliferation is different from that for induction of CD30 expression and IL 4 exerts a pivotal role in CD30 expression of both T and B cells. In addition, T and B cells may show distinct response to other cytokines such as IL 2 in CD30 expression.
Animals ; Antigens, CD30 ; B-Lymphocytes* ; Cell Count ; Cell Proliferation ; Cytokines ; Immunoglobulin M ; Mice ; Up-Regulation

Ki-1 antigen was found by a monoclonal antibody, made against a Hidgkin' disease-derived cell line (L428) that reacted with Reed-Sternberg cells in Hodgkins disease and a few lymphocytes around lymphoid follicle. In 1985, Stein et al identified a large cell anaplastic lymphoma showing a distinctive pleomorphic appearance, sinus growth pattern, and reactivity to Ki-l. We report a case of Ki-1 positive large cell anaplastic lymphoma, which was presenting as a elevated plaque on the skin of popliteal fossa in a 69-year-old female.
Aged ; Antigens, CD30 ; Cell Line ; Female ; Hodgkin Disease ; Humans ; Lymphocytes ; Lymphoma* ; Reed-Sternberg Cells ; Skin

Brentuximab vedotin (BV), a potent antibody-drug conjugate, targets the CD30 antigen. Owing to the remarkable efficacy shown in CD30-positive lymphomas, such as Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma, BV was granted accelerated approval in 2011 by the US Food and Drug Administration. Thereafter, many large-scale trials in various situations have been performed, which led to extensions of the original indication. The aim of this review was to describe the latest updates on clinical trials of BV and the in-practice guidance for the use of BV.
Antigens, CD30 ; Financing, Organized ; Hodgkin Disease ; Lymphoma ; Lymphoma, Large-Cell, Anaplastic ; United States Food and Drug Administration

Ki-1 lymphoma is a rare, large cell anaplastic non Hodgkin's lymphoma. It expresses the CD30 antigen and is recognized by the antibodies Ki-1. This Ki-1 positive anaplastic lymphoma was first described in 1985 as a new histological subtype and was added to the updated Kiel classification in 1988. Morphological and immunological features of this lymphoma have been well described, but clinical studies have been limited and follow up has been short. The authors report a case of Ki-1 lymphoma of the skin without systemic involvement in a young adult based on clinical, pathological and immunological features.
Antibodies ; Antigens, CD30 ; Classification ; Follow-Up Studies ; Humans ; Lymphoma* ; Lymphoma, Large-Cell, Anaplastic ; Lymphoma, Non-Hodgkin ; Skin ; Young Adult*

Gastric Hodgkin's lymphoma is extremely rare. We present a case of primary Hodgkin's lymphoma arising in the stomach of a 65-year-old woman. The patient complained of epigastric discomfort and reflux for one month. Endoscopic examination revealed a protruding lesion characterized by a smooth surface at the antrum. An abdominal computed tomography uncovered a 2.5 x 2.0 cm, exophytic submucosal mass. After the tentative preoperative diagnosis of a gastrointestinal stromal tumor, a gastric wedge resection was performed. Microscopic examination of the mass demonstrated a diffuse proliferation of large atypical lymphoid cells with mono- and binucleated pleomorphic nuclei and prominent nucleoli. Immunohistochemically, the tumor cells were positive for CD30, CD20, and CD79a, whereas they were negative for cytokeratin, carcinoembryonic antigen, CD3, CD15, epithelial membrane antigen, and anaplastic lymphoma kinase-1. Based on the morphological features and immunohistochemical results, in addition to the clinical findings, a diagnosis of primary gastric Hodgkin's lymphoma was established.
Aged ; Antigens, CD30 ; Carcinoembryonic Antigen ; Female ; Gastrointestinal Stromal Tumors ; Hodgkin Disease ; Humans ; Keratins ; Lymphocytes ; Lymphoma ; Mucin-1 ; Stomach

Primary cutaneous large cell lymphomas of the T-cell phenotype are relatively uncommon. Previous studies have revealed the following prognostic variables: the distribution of skin lesions, a history of pre-existing mycosis fungoides, CD30(Ki-1) antigen positivity and anaplastic morphology. CD30 antigen positivity has been associated with an indolent clinical course, in contrast to CD30-negative cases. However, a recent study revealed that multicentric skin lesions confer a worse prognosis on this subgroup of patients rather than the absence of CD30 antigen. p53 immunoreactivity also has been reported to be associated with high grade non-Hodgkin's lymphoma, although it is relatively uncommon. Herein, we report a case of a patient with EBV-related, CD30-negative primary cutaneous large cell lymphoma of the T-cell phenotype showing p53 and mdm-2 expression. She was initially diagnosed as having a benign-looking deep folliculitis or furunculosis, but treated successfully with radiation therapy without recurrence up to now.
Antigens, CD30 ; Folliculitis ; Furunculosis ; Humans ; Lymphoma ; Lymphoma, Non-Hodgkin ; Lymphoma, T-Cell* ; Mycosis Fungoides ; Phenotype ; Prognosis ; Recurrence ; Skin ; T-Lymphocytes*

CD 30 positive anaplastic large cell lymphoma (ALCL) is a type of non-Hodgkin's lymphoma, a tumor that is composed of mostly mast cells expressing CD30 antigens. According to the 2005 World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification, it can be classified as systemic ALCL and primary cutaneous CD30 positive T-cell lymphoproliferative disorder. Systemic ALCL can be subclassified into ALK positive and negative. There have been many cases of primary cutaneous CD30 positive T-cell lymphoproliferative disorder, but reports of systemic ALCL have been rare. We report a case of CD30 positive/ALK negative systemic anaplastic large cell lymphoma involving bone marrow in a 51 year-old-male who showed two pruritic, 1.5x1.0x0.8 cm and 1.0x0.5x0.4 cm sized, erosive, erythematous nodules on the right thigh and calf.
Antigens, CD30 ; Bone Marrow* ; Classification ; Lymphoma, Large-Cell, Anaplastic* ; Lymphoma, Non-Hodgkin ; Lymphoproliferative Disorders ; Mast Cells ; T-Lymphocytes ; Thigh ; World Health ; World Health Organization

Gastric CD30-positive anaplastic large-cell lymphoma is a very rare disease. It is sometimes difficult to distinguish it from undifferentiated carcinoma, sarcoma and so on. We report here on a case of primary gastric anaplastic large-cell lymphoma. A 50-yr-old woman complained of epigastric pain and severe chest pain for 1 week. The gastroendoscopic examination revealed geographic mucosal irregularities with shallow ulceration at the antrum. She underwent a total gastrectomy. The gross finding of the resected stomach was an 8 x 4.5 cm sized ulceroinfiltrative lesion at the pyloric antrum along the lesser curvature. The microscopic examination revealed diffuse and solid proliferations of large atypical cells with pleomorphic nuclei. Immunohistochemically, the tumor cells were positive for CD30, vimentin and CD3, and this was a finding compatible with anaplastic large-cell lymphoma. To the best of our knowledge, this is the first such reported case in Korea.
Antigens, CD30/*metabolism ; Female ; Humans ; Immunohistochemistry ; Korea ; Lymphoma, Large-Cell/enzymology/*immunology/*pathology ; Middle Aged ; Protein-Tyrosine Kinase/metabolism ; Stomach Neoplasms/enzymology/*immunology/*pathology

Primary cutaneous anaplastic large cell lymphoma (PCALCL) is a rare primary cutaneous lymphoma that is predominantly composed of large lymphoid cells that express the CD30 antigen. The skin lesion of PCALCL is usually single, ulcerative, and located on the trunk or extremities and rarely the palm. A 25-year-old woman presented with a plaque on the left palm for 20 days. The plaque was walnut-sized and purple to gray colored with erosion in the center. Histopathologic examination showed infiltration of large atypical cells in the dermis. The large tumor cells showed positivity for CD3, CD4, and CD30 and negativity for CD8, CD20, epithelial membrane antigen, and anaplastic lymphoma kinase. PET-CT showed no other hypermetabolic lesion except that on the left palm, and we finally arrived at a diagnosis of PCALCL. The patient was treated with an intralesional injection of methotrexate (25 mg/mL, 0.45 cc). After 3 months of treatment, the walnut-sized plaque had disappeared and a peripheral hyperpigmented patch remained.
Adult ; Antigens, CD30 ; Dermis ; Diagnosis ; Extremities ; Female ; Humans ; Injections, Intralesional ; Lymphocytes ; Lymphoma ; Lymphoma, Large-Cell, Anaplastic ; Lymphoma, Primary Cutaneous Anaplastic Large Cell* ; Methotrexate ; Mucin-1 ; Phosphotransferases ; Skin ; Ulcer